New Phase 2 Data Show Treatment With Tremfya® (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective an...
Continue Reading →
